Logo

Novartis Reports Results of Galvus (vildagliptin) Combination Therapy in P-IV VERIFY Study for Type 2 Diabetes Mellitus

Share this

Novartis Reports Results of Galvus (vildagliptin) Combination Therapy in P-IV VERIFY Study for Type 2 Diabetes Mellitus

Shots:

  • The P-IV VERIFY study involves assessing of Galvus (50mg- bid) + Metformin (1000–2000 mg- qd) vs SOC monothx. approach with metformin initiated in treatment naïve patients (n=2001) in a ratio (1:1)- recently diagnosed with T2DM across 34 countries for 5yrs.
  • The P-IV VERIFY study resulted in meeting its 1EPs i.e- 49% reduction in the risk for time to initial treatment failure as defined as HbA1c >=7%- showed a lower frequency of secondary failure with consistent safety & tolerability profile
  • Vildagliptin/Metformin dual regimen is the combination of two anti-diabetic agents with complementary mechanism and is the single pill dual therapy of DPP-4 inhibitor with metformin to be approved in Japan & Europe

Click here to­ read full press release/ article | Ref: Novartis | Image: Pharma News


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions